CIK 0001889109 · Large accelerated filer
BELITE BIO, INC
Sign in to watch- Ticker
- BLTE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- other
- Phone
- 858-246-6240
- Business address
- 12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, 92130
- Former names
- BELITE BIO, INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $31,968,735
- in 3 filings, $32.0M under 10b5-1 plans
Net −$31,968,735. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-29 | Chuang Hao-Yuan Chief Financial Officer | Other acquisition | +5,000 | 180,264 | ||
| 2026-10-29 | Lin Yu-Hsin Chief Executive Officer | Other acquisition | +5,000 | 187,949 | ||
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −200 | $163.63 | $33K | 14,800 |
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −24 | $164.64 | $4K | 14,776 |
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −120 | $165.49 | $20K | 14,656 |
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −50 | $166.44 | $8K | 14,606 |
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −78 | $167.59 | $13K | 14,528 |
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −12 | $168.21 | $2K | 14,516 |
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −14 | $169.36 | $2K | 14,502 |
| 2026-10-01 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 | −2 | $170.02 | $340 | 14,500 |
| 2026-09-24 | Chen Wan-Shan Director | Option exercise | +13,796 | $0.44 | $6K | 37,259 |
| 2026-09-24 | Chen Wan-Shan Director | Option exercise · Stock Option (right to buy) | −13,796 | 0 | ||
| 2026-09-08 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 | −2,400 | $194.33 | $466K | 93,734 |
| 2026-09-08 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 | −6,090 | $195.62 | $1.2M | 87,644 |
| 2026-09-08 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 | −6,058 | $196.54 | $1.2M | 81,586 |
| 2026-09-08 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 | −8,752 | $197.36 | $1.7M | 72,834 |
| 2026-09-08 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 | −2,700 | $198.09 | $535K | 70,134 |
| 2026-09-08 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 | −2,200 | $194.28 | $427K | 41,800 |
| 2026-09-08 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 | −4,120 | $195.60 | $806K | 37,680 |
| 2026-09-08 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 | −4,475 | $196.47 | $879K | 33,205 |
Page 1 of 10 · 186 trades